Significance Statement {#s1}
======================

Neurons and neuronal networks display many forms of activity, of which oscillatory activity is crucial in many vital functions such as heartbeat, digestion, and locomotion. The state in which a neuron exists is often determined by its neuromodulatory environment. Recent studies have shown that many neuromodulators that enable oscillatory activity in neurons do so by activating voltage-gated inward currents that express a negative slope conductance. Such voltage gating is normally an intrinsic property of the ion channels themselves and is only rarely mediated by a separate signaling pathway or molecule. Here we characterize what we believe is a novel voltage dependence mechanism that involves active extracellular calcium sensing by a dedicated receptor, and intracellular calcium-dependent processes that modulate the voltage dependence of this current.

Introduction {#s2}
============

Neuromodulators enhance the flexibility of neural networks by multiple mechanisms. These include the regulation of intrinsic properties (i.e., pre-existing conductances; [@B8]; [@B46],[@B47]; [@B34]; [@B25]), modulating synaptic properties ([@B40],[@B41]; [@B97]; [@B9]; [@B10]), reconfiguring participating neurons within the network ([@B37]; [@B23]; [@B50]), and modulating plasticity and even modulation itself ([@B57]; [@B56]; [@B99]; [@B68]; [@B49]). Another important mechanism of the regulation of neuronal excitability is the modulation of leak currents ([@B7]; [@B22]; [@B85]; [@B19]; [@B93]), and of the ratio of leak current to pacemaking current amplitude (and not just the pacemaking current amplitude), as is the case in the regulation of pacemaking activity in the pre-Bötzinger complex ([@B20]). The regulation of inward currents whose current--voltage relationship (*I--V*) curve contains a region of negative slope (i.e., negative conductance) often plays a major role in the control of excitability and pacemaking activity ([@B66]; [@B24]; [@B87]; [@B33]; [@B98]; [@B79]; [@B93]; [@B96]). Such a negative conductance region can be approximated well by an *I--V* curve with linear negative conductance ([@B96]; [@B11]). When this region occurs in the voltage range of oscillatory activity, neuromodulatory regulation of these currents can be thought of as the regulation of leak currents ([@B33]; [@B96]; [@B11]). Recently, it was demonstrated that the negative conductance region of the *I--V* curve of any inward current acts to destabilize the neuronal resting state, thus pushing the membrane potential away from the resting voltage, without the need that the ionic current be nonlinear around the resting potential ([@B11]). The negative conductance of an *I--V* curve is normally generated by an interaction of voltage-dependent ion channel gating and a depolarized equilibrium potential. However, other mechanisms that produce negative conductance exist, such as the voltage-dependent magnesium blockade of the NMDA receptor ([@B66]). Additionally, there are few examples that describe voltage-dependent mechanisms mediated by intracellular signaling pathways ([@B98]; [@B61]; [@B79]).

Here, we use the stomatogastric ganglion (STG) of the crab *Cancer borealis* to explore how the voltage dependence of a neuromodulator-activated current is controlled. This system enables unambiguous cell-type identification and is a practical system for studying negative slope conductance as a mechanism of neuromodulator-induced oscillatory activity ([@B96]; [@B11]). Specifically, we examine the voltage dependence of the modulator-activated inward current (*I*~MI~). This current is thought to be the primary mechanism by which a set of peptide neuromodulators activate the oscillatory activity of the pyloric network ([@B82]), thanks to its region of negative slope conductance ([@B96]). *I*~MI~ was characterized originally as an inward current activated by proctolin, whose voltage dependence is sensitive to extracellular calcium, in the absence of which *I*~MI~ becomes linear ([@B29]). The authors suggested a mechanism similar to that of the NMDA receptor ([@B66]) to explain the nonlinear properties of the current: a voltage-dependent block of the channel by extracellular calcium (rather than magnesium). A later study ([@B82]) found that when exposed to the calmodulin inhibitor *N*-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide hydrochloride (W7), *I*~MI~ amplitude was enhanced and its voltage dependence seemed to be altered, suggesting a modulation of the current by calmodulin. The main hypothesis that we address here is that the voltage dependence of *I*~MI~ is mediated by an extracellular activation of a calcium-sensing mechanism mediated by a calcium-dependent intracellular signaling pathway.

Materials and Methods {#s3}
=====================

Animals {#s3A}
-------

Male crabs of the species *C. borealis* were purchased from local fisheries, housed in saltwater aquaria at 8-12°C, and randomly picked. The animals were anesthetized on ice for at least 30 min prior to dissection. The stomatogastric nervous system (STNS) was dissected out and pinned on Sylgard dishes, as previously described ([@B54]; [@B77]). The isolated STNS was continuously perfused with chilled saline solution (12-14°C), which was composed of the following: 440 m[m]{.smallcaps} NaCl, 11 m[m]{.smallcaps} KCl, 13 m[m]{.smallcaps} CaCl~2~, 26 m[m]{.smallcaps} MgCl~2~, 5 m[m]{.smallcaps} maleic acid, and 11 m[m]{.smallcaps} Trizma base, and was adjusted to a pH of 7.4-7.5. For low-calcium solutions, MgCl~2~ was added in equimolar amounts to compensate for reduced calcium levels. In all experiments, STG neurons and neuropil were exposed by desheathing and pinning down the surrounding connective tissue. Unless otherwise noted, all data reported here were obtained from lateral pyloric (LP) neurons. Concentrations of calcium at or below a concentration of 2 m[m]{.smallcaps} were found to depolarize LP cells (mean resting potential, from −48.9 ± 2.1 to −34.2 ± 2.1 mV; *n* = 9; paired Student's *t* test (*t*~(8)~ = −15.2, *p* = 3.6 × 10^−7^\])^a^ and decrease their input resistance (mean measured at −50 mV; from 9.4 ± 1.8 to 5.4 ± 0.7 MΩ; *n* = 9; *t* test: *t*~(8)~ = 3.5, *p* = 0.008)^b^. To attenuate this effect, low-calcium saline solution was supplemented with 0.5% bovine serum albumin (BSA). This prevented low calcium-induced depolarization (mean resting potential in low-calcium condition: no BSA, −26.0 ± 2.1 mV (*n* = 5); low calcium level plus 0.5% BSA, −45.1 ± 2.4 (*n* = 7); Student's *t* test: *t*~(10)~ = 5.8, *p* = 1.77 × 10^−4c^), but this treatment had no significant effect on input resistance (median input resistance in low-calcium condition: no BSA, 5.5 MΩ; low calcium level plus 0.5% BSA, 6.0 MΩ (*n* = 7); Mann--Whitney rank sum *U* test: *U* = 12, *p* = 0.413^d^). Therefore, all low-calcium experiments were supplemented with 0.5% BSA, except for R568 experiments. R568 was used to test the role of the calcium-sensing receptor (CaSR), but R568 is known be activated by amino acids ([@B18]) and albumin hydrolysates ([@B60]). Because the STG neuropil is known to contain active peptidases ([@B15]), which may release these compounds, BSA was not used when R568 was tested.

Electrophysiology {#s3B}
-----------------

Extracellular recordings were made using Vaseline wells built around lateral ventricular or dorsal ventricular nerves, and with one stainless steel wire inserted in each well and one outside, both connected to an A-M Systems Model 1700 Differential AC Amplifier. Ground electrodes were either AgCl pellets (Molecular Devices) or chloride-coated silver wires (coating was obtained by inserting the silver wire in bleach for ≥15 min). All intracellular recordings, unless otherwise stated, were obtained with an Axoclamp 2B Amplifier (Molecular Devices) and digitized with a Digidata 1322A or 1440 Digitizer (Molecular Devices) and recorded onto a PC with a Microsoft Windows operating system using the pClamp 9 or 10.4 software suite (Molecular Devices). Currents were recorded in two-electrode voltage clamp (TEVC) and passively filtered using an RC filter at a 4 KHz cutoff frequency before digitization. Microelectrodes were pulled on a Sutter P-97 Puller with resistances of 15-25 MΩ for the voltage recording electrode (ME1) and 10-20 MΩ for the current passing electrode (ME2). All recording solutions consisted of 0.6 M K~2~SO~4~ plus 20 m[m]{.smallcaps} KCl.

Neuromodulators {#s3C}
---------------

Proctolin and crustacean cardioactive peptide (CCAP) were used to elicit *I*~MI~ as shown before by [@B82]; see below). Proctolin was purchased from American Peptide or Bachem. CCAP was initially purchased from American Peptide, but in winter 2013 to spring 2014 this peptide did not produce *I*~MI~ values that were comparable to those reported in the literature ([@B82]) and to our own previous results. Thus, all CCAP data from 2013-2014 were omitted, and CCAP used after that was obtained from Bachem. All other neuromodulators were obtained from Sigma-Aldrich.

Solutions and drugs {#s3D}
-------------------

W7, tetraethylammonium (TEA), dynasore, 1-(5-iodonaphthalene-1-sulfonyl)-1H-hexahydro-1,4-diazepine hydrochloride (ML-7), picrotoxin (PTX), Gallein, and fluphenazine came from Sigma-Aldrich. Bis(2-aminophenoxy)ethane-N,N,N\',N\'-tetra-acetic acid-acetoxymethyl ester (BAPTA-AM), tetrodotoxin (TTX), GTPγS, and sometimes W7, came from Tocris Bioscience. Calmidazolium, dantrolene, ryanodine, and pertussis toxin A protomer came from Enzo Life Sciences. CALP1 (sequence, VAITVLVK) and BSA came from Fisher Scientific. *N*-\[2-\[\[\[3-(4-chlorophenyl)-2-propenyl\]methylamino\]methyl\]phenyl\]-*N*-(2-hydroxyethyl)-4-methoxybenzenesulphonamide (KN-93) came from EMD Biosciences. All chemicals were aliquoted in either distilled H~2~O or DMSO and frozen until use.

Measurement of *I*~MI~ {#s3E}
----------------------

Unless otherwise stated, all recordings of *I*~MI~ were made in the following standard recording saline solution: normal *Cancer* saline plus 0.1 μ[m]{.smallcaps} TTX (to block sodium currents), 20 m[m]{.smallcaps} TEA (to block potassium currents), 10 μ[m]{.smallcaps} PTX (to block synaptic currents), 5 m[m]{.smallcaps} CsCl (to block the H-current), and 200 μ[m]{.smallcaps} CdCl~2~ (to block calcium currents). R568 experiments omitted CdCl~2~ as the combination of low calcium without BSA and CdCl~2~ depolarized cells, and reduced viability (data not shown). In some cells, spontaneous oscillations were observed under these conditions. When this happened, TTX and PTX concentrations were transiently raised to 1 and 30 μ[m]{.smallcaps}, respectively, until oscillations stopped or were attenuated. Then, a normal solution was resumed for at least 20 min prior to the measurement of *I*~MI~.

Both proctolin and CCAP were bath applied at 1 μ[m]{.smallcaps} for a volume of 5-10 ml at a perfusion rate of 3-4.5 ml/s. We also tried to use local pressure application of the peptides but found the responses to be too variable, and they were not used here for analysis (data not shown).

All *I*~MI~ recordings were obtained in TEVC. A holding potential of −40 mV was used to prevent contamination from low-threshold activated potassium currents ([@B28]). [Figure 1*A*](#F1){ref-type="fig"} illustrates the procedure used to obtain *I*~MI~. The voltage was ramped from a holding potential of −40 mV, up to +20 mV, down to −80 mV, and back to −40 mV at 75 mV/s. The descending ramp was used to build *I--V* curves and to determine *I*~MI~ properties because it has been shown that the measurement of *I*~MI~ on descending ramps is less sensitive to ramp speed than ascending ramps (D. Fox, personal communication). These ramps were repeated every 35-45 s until no further changes in leak current were observed. At this point, the average of the last three to five ramps was defined as the control ramp ([Fig. 1*A*](#F1){ref-type="fig"}, black trace). The average of three to five ramps at the peak of the response to neuromodulator was measured ([Fig. 1*A*](#F1){ref-type="fig"}, red trace). The control currents were subtracted from the currents in the presence of neuromodulator, and this difference in current ([Fig. 1*A*](#F1){ref-type="fig"}, blue trace) was defined as *I*~MI~. Any data that did not show a reversal of at least 50% of the *I*~MI~ maximum level upon washing were discarded.

![Modulator-activated *I*~MI~ measurement and quantification. ***A***, Proctolin (1 μ[m]{.smallcaps})-induced *I*~MI~ in LP neuron. Top, Voltage ramp protocol. Middle, Current in control ramp (black trace) and at the peak of the response to proctolin (red trace). Bottom, Difference current (blue trace) obtained by subtracting control currents from currents measured in proctolin. Only currents evoked during descending voltage ramps were considered (blue trace). ***B***, *I--V* curves of *I*~MI~ in normal saline solution (13 m[m]{.smallcaps} CaCl~2~, black trace) and low-calcium saline solution (2 m[m]{.smallcaps} CaCl~2~, blue trace). Changes in slope between −75 and −20 mV are used as a measure of *I*~MI~ voltage dependence. Amplitude at −15 mV is taken as a measure of *I*~MI~ activation. Note that *I*~MI~ in normal saline solution is close to maximal at this voltage, and there is minimal difference between normal calcium and low-calcium conditions.](enu0021620530001){#F1}

*I*~MI~ quantification {#s3F}
----------------------

The following two features of *I*~MI~ were quantified from the *I--V* curves throughout: voltage dependence and activation level. Activation was quantified as the amplitude of the current at or near its peak (i.e., at −15 mV), and voltage dependence was quantified as the slope of the *I--V* curve between −75 and −20 mV ([Fig. 1*B*](#F1){ref-type="fig"}). A value of −15 mV was chosen to estimate activation levels because, at this voltage, the amplitude of *I*~MI~ was not sensitive to changes in extracellular calcium \[−1.2 ± 0.3, −2.7 ± 0.9, −2.1 ± 0.2, and −1.5 ± 0.5 nA, for calcium concentrations of 13, 6, 2, and 1 m[m]{.smallcaps}, respectively; one-way ANOVA for calcium concentrations on the second application (see rationale below): *F*~(3,20)~ = 2.37, *p* = 0.10\].^e^ As described in the Results section, this enabled good separation of the effects of various agents on activation from those on voltage dependence. Additionally, this voltage is far enough from the estimated *I*~MI~ reversal potential (mean ± SD, +10.8 ± 9.8 mV, *n* = 43) to allow a reliable measurement of the current. In most of our experiments, *I*~MI~ did not reverse with the protocol used. The reversal potential was estimated only from currents that did reverse, and therefore this average reflects an underestimate of the *I*~MI~ reversal potential, even though it is more depolarized than previous reported estimates (i.e., −2.9 ± 14.7 mV; [@B29]).

In order to evaluate the effects of pharmacological agents on signaling pathways potentially involved in *I*~MI~ activation by proctolin or CCAP, multiple applications of the peptides on each preparation were required. Therefore, we examined the effect of application number on *I*~MI~ amplitude and slope. Under normal calcium conditions, we observed that the first application was significantly larger at −15 mV^f^ and had a significantly more negative slope^g^ than the next four applications ([Table 1](#T1){ref-type="table"}). Amplitude or slope showed no significant differences from one another for applications two to five. Therefore, we used application two as our control application for all data reported here. However, in contrast to normal calcium conditions, when proctolin-induced *I*~MI~ was measured in 2 m[m]{.smallcaps} CaCl~2~ (a low-calcium solution), the amplitude remained unchanged during applications two and three, but dropped significantly with subsequent applications,^h^ while slope remained stable for applications two to five^i^ ([Table 2](#T2){ref-type="table"}). Therefore, low-calcium experiments were statistically analyzed with analysis of covariance (ANCOVA), a mixture of ANOVA and linear regression with drugs understudy as independent factors, and application number as the covariate. This method assumes that the desensitization rate can be predicted by application number, which we find to be true in low-calcium conditions, and is not affected by drug condition. As a consequence of this, *post hoc* testing could not be performed. This was not required for R568 data as only the first application in the low-calcium condition was used.

###### 

Effect of proctolin application sequence on maximum amplitude and slope in normal calcium saline solution

  Application 1   Application 2   Application 3   Application 4   Application 5                                                       
  --------------- --------------- --------------- --------------- --------------- ------------ ------------ ------------ ------------ ------------
  Ampl (nA)       Slope (nS)      Ampl (nA)       Slope (nS)      Ampl (nA)       Slope (nS)   Ampl (nA)    Slope (nS)   Ampl (nA)    Slope (nS)
  (*n* = 7)       (*n* = 7)       (*n* = 7)       (*n* = 7)       (*n* = 7)       (*n* = 7)    (*n* = 7)    (*n* = 7)    (*n* = 5)    (*n* = 5)
  −2.8 ± 0.6\*    −41 ± 10        −1.3 ± 0.3      −17 ± 4         −1.5 ± 0.3      −17 ± 5      −1.1 ± 0.3   −12 ± 3      −1.0 ± 0.3   −12 ± 6

All data were obtained from LP neurons. Ampl, Amplitude.

\*Tukey's test, *p* \< 0.05 vs application 2.

###### 

Effect of proctolin application sequence on maximum amplitude and slope in low-calcium saline solution

  Application 2   Application 3   Application 4   Application 5   Application 6                                                               
  --------------- --------------- --------------- --------------- --------------- ------------ ---------------- ------------ ---------------- ------------
  Ampl (nA)       Slope (nS)      Ampl (nA)       Slope (nS)      Ampl (nA)       Slope (nS)   Ampl (nA)        Slope (nS)   Ampl (nA)        Slope (nS)
  (*n* = 3)       (*n* = 3)       (*n* = 3)       (*n* = 3)       (*n* = 3)       (*n* = 3)    (*n* = 3)        (*n* = 3)    (*n* = 3)        (*n* = 3)
  −2.1 ± 0.9      +26 ± 10        −1.6 ± 0.7      +23 ± 11        −1.1 ± 0.6\*    +19 ± 5      −0.8 ± 0.6\*\*   +22 ± 6      −0.7 ± 0.5\*\*   +18±6

Data are reported as the mean ± SEM. First application was not included as it was performed in normal calcium conditions. All data obtained from LP neurons. Ampl, Amplitude.

\*Tukey's test, *p* \< 0.05 vs application 2 of same calcium condition. *\**\*Tukey test's, *p* \< 0.01 vs application 2 of same calcium condition.

Statistics and data analysis {#s3G}
----------------------------

All calculations of *I*~MI~, and measurements of difference currents and leak subtractions were performed with the pClamp version 9 or 10.4 (Molecular Devices) family of software. All data were digitally filtered after acquisition using an eight-pole Bessel filter with a cutoff frequency of 320 Hz. Data were reduced so that the currents measured during a voltage ramp were divided into 1 mV bins (of ∼13.3 ms each). These data were stored in Microsoft Excel files for databasing and graph making. All statistics were performed with SigmaPlot 11, except for those analyses that required ANCOVA, which were performed with IBM SPSS Statistics 22. Some data were found to be not normal and/or not homoscedastic. For this reason, for two-group comparisons, Mann--Whitney rank sum tests were run. In multiple-group comparisons that failed normality/equal variance testing, the dependent variable was ranked, and statistics were run on this rank score. All data after this transformation passed either an equal variance test (*F* test, SigmaPlot) or Levene's test (SPSS). If data passed normality testing (Shapiro--Wilk test, *p* \> 0.05) after a transformation, statistical testing was performed on the ranked dependent variable. If data failed normality testing after transformation, all statistical testing was performed on the original data. No data failed equal variance testing after rank transformation. All graphs making comparisons between conditions show the average ± SEM, unless noted otherwise. For the majority of experiments, controls and drug applications were performed on alternating days to reduce any biases. [Table 4](#T4){ref-type="table"} summarizes the statistical tests (normality, type of test, and *post hoc* power) and the conditions used in all of the data reported.

Results {#s4}
=======

The reduction of the voltage dependence of *I*~MI~ in low-calcium conditions ([Fig. 1*B*](#F1){ref-type="fig"}) was originally interpreted by [@B29]) as the removal of a voltage-dependent extracellular block of the modulator-activated channels by calcium (similar to the voltage-dependent effect of magnesium on NMDA channels; [@B66]). [@B82] observed that the calmodulin blocker W7 enhanced *I*~MI~ in a voltage-dependent manner and concluded that a calmodulin-dependent pathway was likely involved in *I*~MI~ activation. An alternate interpretation of those results is that the current was not enhanced but instead lost voltage dependence, in a manner similar to the loss of voltage dependence in a low-calcium saline solution, thus explaining why the current was enhanced more at −80 mV than it was at −40 mV ([@B82]). As calmodulin is a ubiquitous calcium sensor, we hypothesized that calmodulin may mediate *I*~MI~ voltage dependence. According to this model, in normal calcium conditions, high levels of calcium influx through calcium channels, or perhaps through *I*~MI~ itself, would keep calmodulin in a relatively activated state. This activated calmodulin would either bind directly to the channel itself or modify *I*~MI~ channels indirectly via calmodulin-activated proteins from a voltage-independent to a voltage-dependent state. When extracellular calcium is reduced, there is less activated calmodulin and therefore reduced voltage dependence. We therefore predicted that full *I--V* relations in the presence of calmodulin inhibitors should reveal a reduced voltage dependence.

The calmodulin inhibitor W7 reduces proctolin and CCAP-induced *I*~MI~ voltage dependence {#s4A}
-----------------------------------------------------------------------------------------

To test the hypothesis that activated calmodulin mediates *I*~MI~ voltage dependence, we measured *I*~MI~ in the presence and absence of the calmodulin inhibitor W7, predicting that W7 should increase *I*~MI~ slope in a dose-dependent manner. As shown in [Figure 2, *Ai* and *Aii*](#F2){ref-type="fig"}, proctolin-induced *I*~MI~ exhibited a negative slope when measured before W7 exposure (black trace). However, at both 10 µ[m]{.smallcaps} W7 ([Fig. 2*Ai*,*Aii*](#F2){ref-type="fig"}, red trace) and 100 µ[m]{.smallcaps} W7 ([Fig. 2*Ai*,*Aii*](#F2){ref-type="fig"}, blue trace), this slope becomes increasingly more positive. When these experiments were repeated at various concentrations of W7, it was found that W7 increased proctolin-induced *I*~MI~ slope in a dose-dependent manner. A one-way repeated-measures ANOVA showed that W7 significantly changed the *I*~MI~ slope (*F*~(4,19)~ = 15.972, *p* = 6.96 × 10*^−^* ^6j^). A *post hoc* Tukey's test showed that these changes were significant at concentrations of ≥10 µ[m]{.smallcaps} ([Fig. 2*Aiii*](#F2){ref-type="fig"}). Interestingly, a one-way repeated-measures ANOVA showed that W7 changed proctolin-induced *I*~MI~ amplitude at −15 mV (*F*~(4,19)~ = 3.243, *p* = 0.035^k^). However, this appeared to be a biphasic effect, because *post hoc* tests revealed that only at a concentration of 10 µ[m]{.smallcaps} was the amplitude significantly different from that of controls, but not at higher concentrations (data not shown). We also replicated these results for 1 µ[m]{.smallcaps} CCAP (control slope = −0.013 ± 0.003 µS; 33 µ[m]{.smallcaps} W7 slope = −0.003 ± 0.003; paired Student's *t* test (*t*~(5)~ = −2.625, *p* = 0.047, *n* = 6^l^; see also [Fig. 8](#F8){ref-type="fig"}). In contrast, no significant effect on amplitude at −15 mV was found for CCAP-induced *I*~MI~ (paired Student's *t* test: *t*~(5)~ = −0.435, *p* = 0.681, *n* = 6^m^), but concentrations of W7 \<33 µ[m]{.smallcaps} were not tested for CCAP-induced *I*~MI~. The findings for CCAP-activated *I*~MI~ support the hypothesis that activated calmodulin mediates *I*~MI~ voltage dependence.

![The effect of calmodulin inhibitors on *I*~MI~ voltage dependence. Left, Proctolin-induced *I*~MI~ at different concentrations of W7. ***Ai***, Representative *I--V* curves of a W7 experiment. ***Aii***, Averaged *I--V* curves across W7 experiments. ***Aiii***, Quantification of W7 data. A one-way repeated-measures ANOVA showed that W7 changed the proctolin-induced *I*~MI~ slope (*F*~(4,19)~ = 15.972, *p* = 6.96 × 10^−6j^). Error bars indicate the SEM. Tukey's test; \**p* \< 0.05; \*\*\**p* \< 0.001. Right, Proctolin-induced *I*~MI~ in different concentrations of calmidazolium (CDZ). ***Bi***, Representative *I--V* curves. ***Bii***, Average *I--V* curves from all calmidazolium experiments. ***Biii***, Quantification of all calmidazolium data. A one-way repeated-measures ANOVA showed that calmidazolium significantly altered *I*~MI~ slope (*F*~(3,9)~ = 4.846, *p* = 0.028^n^). However, no significant *post hoc* pairwise differences were observed. Tukey's *post hoc* test, *p* \< 0.05. Error bars indicate the SEM. Data are from LP neurons.](enu0021620530002){#F2}

The calmodulin inhibitor calmidazolium reduces *I*~MI~ voltage dependence {#s4B}
-------------------------------------------------------------------------

Although W7 increases neuromodulator-induced *I*~MI~ slope, and it has been shown to inhibit calmodulin-dependent effects in other crab species ([@B69]), it is known to also have nonspecific effects on calmodulin-activated proteins and calmodulin-like proteins. For example, W7 has been shown to directly inhibit calmodulin-activated proteins themselves, such as myosin light chain kinase (MLCK), independent of calmodulin activity ([@B39]; [@B75]), and it has been used both to purify ([@B86]) and to inhibit ([@B58]) other EF-hand domain proteins. Thus, having no known direct assay for calmodulin function in this system, we decided to use structurally different calmodulin inhibitors, and selected non-naphthalene--sulfonamide calmodulin inhibitors fluphenazine and calmidazolium. The D~1~/D~2~ receptor antagonist, and calmodulin inhibitor, fluphenazine appeared to be toxic to our cells at concentrations far below those required for calmodulin inhibition (1 m[m]{.smallcaps}) in crayfish muscle ([@B76]; *n* = 3; data not shown). Calmidazolium showed no toxic effects and increased *I*~MI~ slope in a dose-dependent manner ([Fig. 2*Bi*,*Bii*](#F2){ref-type="fig"}). A one-way repeated-measures ANOVA showed that calmidazolium significantly altered *I*~MI~ slope (*F*~(3,9)~ = 4.846, *p* = 0.028^n^), although *post hoc* analysis did not show specific concentration effects ([Fig. 2*Biii*](#F2){ref-type="fig"}). This is consistent with the hypothesis that activated calmodulin mediates *I*~MI~ voltage dependence. Interestingly, a one-way repeated-measures ANOVA test showed that calmidazolium also significantly altered *I*~MI~ amplitude at −15 mV (*F*~(3,9)~ = 6.382, *p* = 0.013^o^). This reduction in *I*~MI~ amplitude is consistent with that observed for proctolin-induced *I*~MI~ at 10 µ[m]{.smallcaps} concentration of W7 shown previously. All three experiments (W7 on both proctolin and CCAP-activated *I*~MI~, and calmidazolium on proctolin-activated *I*~MI~), however, showed a consistent inhibitory effect on slope, supporting the hypothesis that activated calmodulin mediates both proctolin- and CCAP-induced *I*~MI~ voltage dependence.

The calmodulin agonist CALP1 does not restore *I*~MI~ voltage dependence in low calcium {#s4C}
---------------------------------------------------------------------------------------

As the preceding results suggested that activated calmodulin mediated the voltage dependence of *I*~MI~, we predicted that calmodulin agonists should be able to restore *I*~MI~ voltage dependence in a low-extracellular calcium solution. We applied the calmodulin activator CALP1, a membrane-permeable peptide that locks the EF-hand domains of calmodulin in the "on state," thus bypassing the requirement for calcium ([@B53]), with the prediction that this should make the *I*~MI~ slope more negative in low-calcium solutions. Two hour incubations of CALP1 at 1 µ[m]{.smallcaps} (*n* = 4), 10 µ[m]{.smallcaps} (*n* = 4), and 50 µ[m]{.smallcaps} (*n* = 2) showed no significant effect on proctolin-induced *I*~MI~ slope (one-way ANOVA: *F*~(3,16)~ = 1.077, *p* = 0.387)^p^ or amplitude (one-way ANOVA: *F*~(3,16)~ = 0.437, *p* = 0.729)^q^ in a low-calcium saline solution ([Table 3](#T3){ref-type="table"}). Similarly, when this experiment was repeated with overnight incubations in 50 µ[m]{.smallcaps} CALP1 (*n* = 3), no difference was observed compared with control solutions (*n* = 2) for either slope (Student's *t* test: *t*~(3)~ = 0.44, *p* = 0.689)^r^ or amplitude (Student's *t* test: *t*~(3)~ = 0.777, *p* = 0.494^s^). We do not have a satisfactory explanation for these results at this point, except that CALP1 may not be effective in crustaceans or that, once calmodulin is dislodged from the receptor because of the low-calcium condition, it cannot be reactivated by CALP1 (see Discussion).

###### 

Drugs that affected *I*~MI~ slope

  Drug name             \[Drug\]                  \[Ca\]                Neuromodulator   *n*           *I*~MI~ slope (nS)
  --------------------- ------------------------- --------------------- ---------------- ------------- --------------------
  W7                    0 µ[m]{.smallcaps}        13 m[m]{.smallcaps}   Proctolin        12            −21.7 ± 3.7
                        0.1 µ[m]{.smallcaps}      13 m[m]{.smallcaps}   Proctolin        5             −13.5 ± 4.2
                        1 µ[m]{.smallcaps}        13 m[m]{.smallcaps}   Proctolin        6             −11.2 ± 2.4\*
                        10 µ[m]{.smallcaps}       13 m[m]{.smallcaps}   Proctolin        6             −11.4 ± 3.9\*\*
                        100 µ[m]{.smallcaps}      13 m[m]{.smallcaps}   Proctolin        6             +13.1 ± 3.4\*\*\*
  Calmidazolium         0 µ[m]{.smallcaps}        13 m[m]{.smallcaps}   Proctolin        6             −20.4 ± 10.6
                        0.1 µ[m]{.smallcaps}      13 m[m]{.smallcaps}   Proctolin        2             −13.7 ± 11.1
                        0.3 µ[m]{.smallcaps}      13 m[m]{.smallcaps}   Proctolin        6             +1.6 ± 14
                        0.0 µ[m]{.smallcaps}      13 m[m]{.smallcaps}   Proctolin        4             +4.3 ± 4.9
  Dantrolene            0 µ[m]{.smallcaps}        13 m[m]{.smallcaps}   Proctolin        6             −8.1 ± 3.2
                        3.3 µ[m]{.smallcaps}      13 m[m]{.smallcaps}   Proctolin        6             +1.6 ± 1.9\*\*
  CALP1                 0 µ[m]{.smallcaps}        2 m[m]{.smallcaps}    Proctolin        11            +18.2 ± 4.9
                        1 µ[m]{.smallcaps}        2 m[m]{.smallcaps}    Proctolin        4             +10.2 ± 6.4
                        10 µ[m]{.smallcaps}       2 m[m]{.smallcaps}    Proctolin        4             +28.2 ± 3.8
                        50 µ[m]{.smallcaps}       2 m[m]{.smallcaps}    Proctolin        2             +23.5 ± 9.4
  KN-93                 0 µ[m]{.smallcaps}        13 m[m]{.smallcaps}   Proctolin        7             −21 ± 4.2
                        Low dose                  13 m[m]{.smallcaps}   Proctolin        5             +0.8 ± 5.8
                        High dose                 13 m[m]{.smallcaps}   Proctolin        2             +16.6 ± 2.2
  Pertussis toxin       0 µg/ml                   13 m[m]{.smallcaps}   Proctolin        7             −3.1 ± 2.9
                        0 µg/ml                   2 m[m]{.smallcaps}    Proctolin        6             +14.4 ± 3.1
                        10 µg/ml                  13 m[m]{.smallcaps}   Proctolin        7             +1.5 ± 2.9
                        10 µg/ml                  2 m[m]{.smallcaps}    Proctolin        6             +21.5 ± 3.1
  GTPγS                 0 m[m]{.smallcaps}        13 m[m]{.smallcaps}   Proctolin        9             −2.2 ± 2.9
  0 m[m]{.smallcaps}    2 m[m]{.smallcaps}        Proctolin             8                +11.5 ± 3.1   
  10 m[m]{.smallcaps}   13 m[m]{.smallcaps}       Proctolin             5                −6.7 ± 4.0    
                        10 m[m]{.smallcaps}       2 m[m]{.smallcaps}    Proctolin        4             +15.2 ± 4.4
  Gallein               0 µ[m]{.smallcaps}        13 m[m]{.smallcaps}   Proctolin        9             −5.4 ± 1.6
                        1 µ[m]{.smallcaps}        13 m[m]{.smallcaps}   Proctolin        9             +1.5 ± 1.9\*
                        3 µ[m]{.smallcaps}        13 m[m]{.smallcaps}   Proctolin        9             +0.7 ± 2.8
  ML-7                  0 µ[m]{.smallcaps}        13 m[m]{.smallcaps}   Proctolin        12            −4.2 ± 1.5
                        0.1 µ[m]{.smallcaps}      13 m[m]{.smallcaps}   Proctolin        12            +1.7 ± 2.3\*
                        1 µ[m]{.smallcaps}        13 m[m]{.smallcaps}   Proctolin        10            +4.5 ± 1.4\*\*\*
                        10 µ[m]{.smallcaps}       13 m[m]{.smallcaps}   Proctolin        7             +3.1 ± 2.4\*
  Dynasore, W7          0, 0 µ[m]{.smallcaps}     13 m[m]{.smallcaps}   CCAP             18            −11.3 ± 1.3
                        0, 33 µ[m]{.smallcaps}    13 m[m]{.smallcaps}   CCAP             6             −0.4 ± 2.3\*\*\*
                        33, 0 µ[m]{.smallcaps}    13 m[m]{.smallcaps}   CCAP             6             −12.6 ± 2.3
                        33, 33 µ[m]{.smallcaps}   13 m[m]{.smallcaps}   CCAP             6             −7.7 ± 2.3†
  R568                  0 µ[m]{.smallcaps}        13 m[m]{.smallcaps}   Proctolin        10            −0.7 ± 4.5
                        0 µ[m]{.smallcaps}        2 m[m]{.smallcaps}    Proctolin        6             +16.5 ± 5.9
                        10 µ[m]{.smallcaps}       13 m[m]{.smallcaps}   Proctolin        4             +17.3 ± 7.2\*
                        10 µ[m]{.smallcaps}       2 m[m]{.smallcaps}    Proctolin        4             +36.9 ± 7.2‡

Data are reported as the mean ± SEM. All data were obtained from LP neurons.

Tukey's test/*t* test *p* value vs control: \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001; †p \< 0.05 vs W7 alone; ‡*p* \< 0.05 vs low-calcium control.

###### 

Statistical tests

  Letter, experiment name                                                   Data structure (distribution)   Type of test                                              Power (α = 0.05)
  ------------------------------------------------------------------------- ------------------------------- --------------------------------------------------------- ----------------------------------------------------
  ^a^ Low-calcium effect on RMP                                             Normal                          Two-tailed paired *t* test                                1.00
  ^b^ Low-calcium effect on R~in~                                           Normal                          Two-tailed paired *t* test                                0.84
  ^c^ BSA effect on low calcium-induced depolarization                      Normal                          Two-tailed *t* test                                       1.00
  ^d^ BSA effect on low calcium-induced effects of R~in~                    Non-normal                      Mann--Whitney rank sum test                               0.17\*
  ^e^ Effect of low calcium on I~MI~ amplitude                              Normal                          One-way ANOVA                                             0.30
  ^f^ Effect of application number on I~MI~ amplitude in normal calcium     Normal                          One-way ANOVA, post hoc Tukey's tests                     0.81
  ^g^ Effect of application number on slope in normal calcium               Normal                          One-way ANOVA, post hoc Tukey's tests                     0.81
  ^h^ Effect of application number on I~MI~ amplitude in low calcium        Normal                          Two-way repeated-measures ANOVA, post hoc Tukey's tests   Calcium = 0.05Application = 0.90Interaction = 0.59
  ^i^ Effect of application number on slope in low calcium                  Normal                          Two-way repeated-measures ANOVA, post hoc Tukey's tests   Calcium = 0.94Application = 0.05Interaction = 0.13
  ^j^ W7 effect on proctolin-induced I~MI~ slope                            Normal                          One-way repeated-measures ANOVA, post hoc Tukey's tests   1.00
  ^k^ W7 effect on proctolin-induced I~MI~ amplitude                        Normal                          One-way repeated-measures ANOVA, post hoc Tukey's tests   0.54
  ^l^ W7 effect on CCAP-induced I~MI~ slope                                 Normal                          Two-tailed paired t test                                  0.50
  ^m^ W7 effect on CCAP-induced I~MI~ amplitude                             Normal                          Two-tailed paired t test                                  0.05
  ^n^ Effect of calmidazolium on proctolin-induced I~MI~ slope              Normal                          One-way repeated-measures ANOVA, post hoc Tukey's tests   0.62
  ^o^ Effect of calmidazolium effect on proctolin-induced I~MI~ amplitude   Normal                          One-way repeated-measures ANOVA, post hoc Tukey's tests   0.78
  ^p^ Effect of CALP1 (2 h) on proctolin-induced I~MI~ slope                Normal                          One-way ANOVA                                             0.07
  ^q^ Effect of CALP1 (2 h) on proctolin-induced I~MI~ amplitude            Normal                          One-way ANOVA                                             0.05
  ^r^ Effect of CALP1 (overnight) on proctolin-induced I~MI~ slope          Normal                          Two-tailed t test                                         0.10
  ^s^ Effect of CALP1 (overnight) on proctolin-induced I~MI~ amplitude      Normal                          Two-tailed t test                                         0.10
  ^t^ Dantrolene effect on proctolin-induced I~MI~ slope                    Normal                          Two-tailed paired t test                                  0.91
  ^u^ Dantrolene effect on proctolin-induced I~MI~ amplitude                Normal                          Two-tailed paired t test                                  0.77
  ^w^ KN-93 effect on proctolin-induced I~MI~ slope                         Normal                          One-way repeated-measures ANOVA, post hoc Tukey's tests   1.00
  ^x^ KN-93 effect on proctolin-induced I~MI~ amplitude                     Normal                          One-way repeated-measures ANOVA, post hoc Tukey's tests   1.00
  ^y^ Effect of gallein on proctolin-induced I~MI~ slope                    Normal                          One-way repeated-measures ANOVA, post hoc Tukey's tests   0.56
  ^z^ Effect of gallein on proctolin-induced I~MI~ amplitude                Normal                          One-way repeated-measures ANOVA, post hoc Tukey's tests   0.13
  ^aa^ Effect of NPS-2143 on proctolin-induced I~MI~ slope                  Normal                          One-way repeated-measures ANOVA, post hoc Tukey's tests   0.57
  ^ab^ Effect of NPS-2143 on proctolin-induced I~MI~ amplitude              Normal                          One-way repeated-measures ANOVA, post hoc Tukey's tests   0.06
  ^ac^ ML7 effect on proctolin-induced I~MI~ slope                          Normal                          One-way repeated-measures ANOVA, post hoc Tukey's tests   0.95
  ^ad^ ML7 effect on proctolin-induced I~MI~ amplitude                      Normal                          One-way repeated-measures ANOVA, post hoc Tukey's tests   0.71
  ^ae^ Effect of dynasore on W7's reduction of I~MI~ voltage dependence     Normal                          Two-way ANOVA, post hoc Tukey's tests                     W7 = 0.99Dynasore = 0.55Interaction = 0.26
  ^af^ Effect of dynasore on effect of W7 on I~MI~ amplitude                Normal                          Two-way ANOVA, post hoc Tukey's tests                     W7 = 0.88Dynasore = 0.10Interaction = 0.17
  ^ag^ R568 effect on proctolin-induced I~MI~ slope                         Normal                          Two-way ANOVA, post hoc Tukey's tests                     Calcium = 0.86R568 = 0.89Interaction = 0.10
  ^ah^ R568 effect on proctolin-induced I~MI~ amplitude                     Non-normal                      Two-way ANOVA, post hoc Tukey's tests                     Calcium = 1.00R568 = 1.00Interaction = 0.70

All data obtained from LP neurons. RMP is resting membrane potential, Rin is input resistance.

\**Post hoc* power calculation performed for *t* test.

Intracellular calcium effects {#s4D}
-----------------------------

Our hypothesis that calcium-activated calmodulin mediates *I*~MI~ voltage dependence can be tested (indirectly) by lowering the intracellular calcium concentration, with the prediction that this will reduce activated calmodulin level and in turn decrease *I*~MI~ voltage dependence (i.e., increase the *I*~MI~ slope).

### The calcium chelator BAPTA-AM does not alter *I*~MI~ or the transient high-threshold potassium current {#s4D1}

In order to lower intracellular calcium concentrations, we tried both incubating preparations in 30 µ[m]{.smallcaps} membrane-permeable calcium chelator BAPTA-AM for 2 h (*n* = 6), and overnight (∼18 h) at 30 µ[m]{.smallcaps} (*n* = 3) and 100 µ[m]{.smallcaps} (*n* = 5). In all of these experiments, no significant changes in *I*~MI~ slope or amplitude were observed (data not shown). Surprisingly, we also saw no change in the high-threshold potassium current (*I*~HTK~). *I*~HTK~ is dominated by a large Ca-dependent potassium current ([@B32]; [@B28]) and was thus expected to be greatly affected. We conclude that BAPTA-AM may be ineffectual in these cells (cells may lack the intracellular esterases or BAPTA may be locked in the wrong intracellular compartment after de-esterification) or its buffering capacity may be too small to handle the large influx of calcium in this system. These observations are consistent with similar observations in *C. borealis* cardiac ganglion neurons in which *I*~HTK~ was also unaffected by BAPTA-AM ([@B73]). Our attempts to inject BAPTA directly into a different cell type, the pyloric dilator, PD, cell by iontophoresis (*n* = 3) produced inconsistent and inconclusive results, presumably because of the effects of current injection on *I*~HTK~, such as those reported by [@B30].

### The ryanodine receptor antagonist dantrolene reduces *I*~MI~ voltage dependence {#s4D2}

We found that incubation with the ryanodine receptor antagonist dantrolene, a known inhibitor of ryanodine receptors in crustaceans ([@B67]; [@B72]) was effective in changing the *I*~MI~ slope. As ryanodine receptors mediate calcium-induced calcium release ([@B95]), incubation in dantrolene was expected to lower intracellular calcium levels and thus reduce *I*~MI~ voltage dependence. Indeed, incubation in 3.33 µ[m]{.smallcaps} dantrolene reduced proctolin-induced *I*~MI~ voltage dependence ([Fig. 3](#F3){ref-type="fig"}). [Figure 3*A*](#F3){ref-type="fig"} shows a representative example, and [Figure 3*B*](#F3){ref-type="fig"} shows the averages from a set of six experiments. A paired two-tailed Student's *t* test showed that dantrolene significantly increased *I*~MI~ slope (*t*~(5)~ = −4.230, *p* = 0.008^t^; [Fig. 3*C*](#F3){ref-type="fig"}). This is consistent with the hypothesis that calcium-activated calmodulin is necessary for *I*~MI~ voltage dependence. Dantrolene also significantly decreased *I*~MI~ amplitude at −15 mV (paired Student's *t* test: *t*~(5)~ = −3.502, *p* = 0.017^u^). These results are consistent with our previous calmodulin inhibitor results, which suggest a dual role for intracellular calcium and calmodulin in the regulation of *I*~MI~ voltage dependence and activation.

![The ryanodine antagonist dantrolene reduces *I*~MI~ voltage dependence. ***A***, Representative *I--V* curve of the proctolin-induced *I*~MI~ before (black trace) and after (red trace) application of 3.33 μ[m]{.smallcaps} dantrolene. ***B***, Averaged *I--V* curves of all dantrolene experiments. ***C***, Quantification of dantrolene data shown in ***B***. A paired two-tailed Student's *t* test showed that dantrolene significantly increased proctolin-induced *I*~MI~ slope (*t*~(5)~ = −4.230, *p* = 0.008^t^). \**p* \< 0.05. Error bars indicate the SEM. Recordings are from LP neurons.](enu0021620530003){#F3}

Role of calmodulin-activated kinases in *I*~MI~ voltage dependence {#s4E}
------------------------------------------------------------------

In order to determine whether calmodulin-activated proteins play a role in *I*~MI~ voltage dependence, we investigated inhibitors of calmodulin-activated kinases and phosphatases. In fact, the best known case of voltage dependence mediated by an intracellular signaling cascade is that of "on" bipolar cells of dogfish retina that was described by [@B78] and appears to require the activation of CaMKII. Therefore, we first examined the effects of the membrane-permeable CaMKII inhibitor KN-93, an inhibitor that has been successfully used in crayfish neurons ([@B88]). We predicted that KN-93 should reduce *I*~MI~ voltage dependence. As shown in [Figure 4, *A* and *B*](#F4){ref-type="fig"}, KN-93 applied for ∼2 h reduced proctolin-induced *I*~MI~ voltage dependence in a dose-dependent manner. [Figure 4*A*](#F4){ref-type="fig"} illustrates the gradual increase in slope observed 50 min after washout (solid green trace) and then 110 min after washout (dashed green trace) from KN-93 application. For statistical analysis, due to the low sample number, these groups were divided into a control condition, a "low-dose" KN-93 condition consisting of the combined data for KN-93 at 2 μ[m]{.smallcaps} (*n* = 1), 4 μ[m]{.smallcaps} (*n* = 1), and 5 μ[m]{.smallcaps} (*n* = 3), and a "high dose" KN-93 condition corresponding to the combined data for KN-93 at 10 μ[m]{.smallcaps} (*n* = 1) and 20 μ[m]{.smallcaps} (*n* =1). A one-way repeated-measures ANOVA showed that KN-93 significantly increased proctolin-induced *I*~MI~ slope (*F*~(2,5)~ = 46.24, *p* = 5.96 × 10^−4w^). A *post hoc* Tukey's test shows that both the low-dose (*p* = 0.004) and high-dose (*p* = 0.002) conditions were significantly different from control and from one another (*p* = 0.043). On the other hand, a one-way repeated-measures ANOVA also showed that KN-93 significantly decreased the amplitude of proctolin-induced *I*~MI~ at −15 mV (*F*~(2,5)~ = 34.09, *p* = 0.001),^x^ with a *post hoc* Tukey's test showing that both the low dose (*p* = 0.013) and high dose (*p* = 0.003) conditions were significantly different from control and from one another (*p* = 0.034). Combined with the finding that a CaMKII-like enzyme has been identified in the stomatogastric nervous system of crustaceans ([@B92]), our results suggest that CaMKII plays a dual role in both *I*~MI~ voltage dependence and activation.

![The CaMKII inhibitor KN-93 reduces *I*~MI~ voltage dependence. Proctolin-induced *I*~MI~ at different concentrations of KN-93. For statistical analysis, KN-93 was grouped into a low-dose (2-5 μ[m]{.smallcaps}) and a high-dose (10-20 μ[m]{.smallcaps}) group, in addition to a control group (0 μ[m]{.smallcaps}). ***A***, Representative *I--V* curves for a KN-93 experiment. ***B***, Averaged *I--V* curves for all KN-93 experiments. ***C***, Quantification of data shown in ***B***. A one-way repeated-measures ANOVA showed that KN-93 significantly increased proctolin-induced *I*~MI~ slope (*F*~(2,5)~ = 46.239, *p* = 5.96 × 10^−4w^). Recordings are from LP neurons.](enu0021620530004){#F4}

The calcium-sensing receptor hypothesis {#s4F}
---------------------------------------

The results reported so far are clearly not consistent with the original hypothesis of [@B29]) of an extracellular voltage-dependent block of *I*~MI~ channels by calcium. Instead, it indicates a clear role of extracellular calcium mediated by a calmodulin-dependent mechanism.

We hypothesized that the activation by extracellular calcium of CaSRs, which are known to require binding of activated calmodulin for their stable expression on the cell surface ([@B38]), might explain the voltage dependence of *I*~MI~. CaSRs are known to be G-protein-coupled receptors of the metabotropic glutamate receptor family ([@B18]; [@B16]; [@B38]), and we propose that the activation of such a G-protein-coupled CaSR provides a voltage dependence signal to *I*~MI~ (see [Fig. 10](#F10){ref-type="fig"}). According to this model, in a low-calcium saline solution, the CaSR ligand is missing, which leads to the observed loss of voltage dependence. This would also explain the loss of voltage dependence in the presence of calmodulin inhibitors, which are known to destabilize the receptor and lead to its subsequent endocytosis ([@B38]). Below, we test this hypothesis.

The βγ-subunit inhibitor gallein decreases *I*~MI~ voltage dependence {#s4G}
---------------------------------------------------------------------

The CaSR is a member of the (class 3/C) G-protein-coupled metabotropic glutamate receptor family, typically associated with G~q~ or G~i~ signaling ([@B18]; [@B16]; [@B38]). No commercially available inhibitors of G~q~ are currently available. Thus, we targeted G~i~ by using the G~o~/G~i~ inhibitor pertussis toxin as well as the nonhydrolyzable GTP derivative GTPγS and detected no changes in the slope of *I*~MI~ ([Table 3](#T3){ref-type="table"}). Similarly, we saw no evidence that G~i~ was involved, because the pertussis toxin did not produce changes to the *I*~MI~ slope ([Table 3](#T3){ref-type="table"}). To test the possibility that the Gβγ-subunits may be involved, we examined the effects of the inhibitor gallein and found that it significantly reduced the proctolin-induced *I*~MI~ voltage dependence ([Fig. 5*A*,*B*](#F5){ref-type="fig"}). As shown in [Figure 5, *A* and *B*](#F5){ref-type="fig"}, increasing concentrations of gallein increased proctolin-induced *I*~MI~ slope in a dose-dependent manner ([Table 3](#T3){ref-type="table"}). A one-way repeated-measures ANOVA showed that this effect was statistically significant (*F*~(2,16)~ = 4.445, *p* = 0.029^y^), with concentrations of 1 μ[m]{.smallcaps} already at saturation level ([Fig. 5*C*](#F5){ref-type="fig"}). Importantly, this modulation appeared to be independent of *I*~MI~ activation, because a one-way repeated-measures ANOVA showed that gallein did not significantly change *I*~MI~ amplitude at −15 mV (*F*~(2,16)~ = 2.337, *p* = 0.129^z^). These results suggest that *I*~MI~ voltage dependence may be modulated by G-protein-coupled receptors, specifically via βγ-subunits of heterotrimeric G-proteins.

![The Gβγ-subunit inhibitor gallein increases *I*~MI~ slope. ***A***, Representative *I--V* curves of proctolin-induced *I*~MI~ in gallein. ***B***, Averaged *I--V* curves of proctolin-induced *I*~MI~ for all gallein experiments. ***C***, Quantification of the data shown in ***A***. ***B***, A one-way repeated-measures ANOVA showed that gallein significantly increased proctolin-induced *I*~MI~ slope (*F*~(2,16)~ = 4.445, *p* = 0.029^y^). Error bars indicate the SEM. Tukey's test, \**p* \< 0.05. Recordings are from LP neurons.](enu0021620530005){#F5}

The specific CaSR antagonist NPS-2143 reduces *I*~MI~ voltage dependence {#s4H}
------------------------------------------------------------------------

If *I*~MI~ voltage dependence is due to signaling by CaSR, then the specific CaSR antagonist NPS-2143 should increase *I*~MI~ slope in a dose-dependent manner. As shown in [Figure 6, *A* and *B*](#F6){ref-type="fig"}, NPS-2143 applied in the presence of normal calcium levels increased proctolin-induced *I*~MI~ slope. A one-way repeated-measures ANOVA showed that NPS-2143 significantly altered proctolin-induced *I*~MI~ slope (*F*~(4,22)~ = 3.314, *p* = 0.029^aa^; [Fig. 6*C*](#F6){ref-type="fig"}, [Table 3](#T3){ref-type="table"}). In contrast, a one-way repeated-measures ANOVA showed that NPS-2143 did not significantly alter *I*~MI~ amplitude at −15 mV \[*F*~(4,22)~ = 1.085, *p* = 0.388^ab^). These results are consistent with the hypothesis that *I*~MI~ voltage dependence is mediated by active detection of extracellular calcium by a CaSR.

![The specific CaSR antagonist NPS-2143 increases *I*~MI~ slope in a normal calcium condition in LP neurons. ***A***, Representative *I--V* curves showing the effect of NPS-2143 (NPS) at different concentrations on proctolin-induced *I*~MI~. ***B***, Averaged *I--V* curves of all NPS-2143 experiments. ***C***, Quantification of all NPS-2143 data. A one-way repeated-measures ANOVA showed that NPS-2143 significantly altered proctolin-induced *I*~MI~ slope (*F*~(4,22)~ = 3.314, *p* = 0.029^aa^). Error bars indicate the SEM. Tukey's test, \**p* \< 0.05.](enu0021620530006){#F6}

The MLCK inhibitor ML-7 reduces *I*~MI~ voltage dependence {#s4I}
----------------------------------------------------------

MLCK is inhibited by W7 independently of calmodulin ([@B39]). It is involved in both muscarinic ([@B81]) and noradrenergic ([@B3]) activation of sodium-permeable voltage-gated cationic currents in mammalian smooth muscle and bradykinin-induced reductions in manganese influx (and, presumably, intracellular calcium) in endothelial cells ([@B84]). However, most importantly, MLCK has been proposed to act downstream of CaSR signaling ([@B18]). For these reasons, we measured proctolin-induced *I*~MI~ in the presence of the specific MLCK inhibitor ML-7, which is known to be effective in other crustacean systems ([@B94]; [@B13]). Our prediction was that, if MLCK mediates CaSR signaling, we should observe a dose-dependent increase in *I*~MI~ slope. As shown in [Figure 7, *A* and *B*](#F7){ref-type="fig"}, ML-7 increased proctolin-induced *I*~MI~ slope in a dose-dependent manner. A one-way repeated-measures ANOVA showed that ML-7 significantly increased proctolin-induced *I*~MI~ slope (*F*~(3,26)~ = 7.503, *p* = 8.92 × 10^−4ac^; [Fig. 7*C*](#F7){ref-type="fig"}, [Table 3](#T3){ref-type="table"}), which is consistent with our hypothesis that CaSR mediates *I*~MI~ voltage dependence. A *post hoc* Tukey's test showed that this was significant at concentrations as low as 0.1 µ[m]{.smallcaps} (*p* = 0.024). ML-7 also appeared to reduce proctolin-induced *I*~MI~ amplitude at high concentrations. A one-way repeated-measures ANOVA showed that ML-7 decreased proctolin-induced *I*~MI~ amplitude at −15 mV (*F*~(3,26)~ = 4.468, *p* = 0.012^ad^), with a *post hoc* Tukey's test showing that this inhibition was significant only at concentrations of ≥1 µ[m]{.smallcaps} (*p* = 0.035; data not shown).

![The MLCK inhibitor ML-7 reduces the voltage dependence of *I*~MI~ in LP neurons. ***A***, Representative *I--V* traces of proctolin-induced *I*~MI~ in the presence of various concentrations of ML-7. ***B***, Averaged *I--V* traces for all ML-7 experiments. ***C***, A one-way repeated-measures ANOVA showed that ML-7 increased proctolin-induced *I*~MI~ slope (*F*~(3,26)~ = 7.503, *p* = 8.92 × 10^−4ac^). Error bars indicate the SEM. Tukey's test: \**p* \< 0.05; \*\**p* \< 0.01; \*\*\**p* \< 0.001.](enu0021620530007){#F7}

Preincubation in the endocytosis inhibitor dynasore prevents W7-induced reduction in voltage dependence {#s4J}
-------------------------------------------------------------------------------------------------------

If the loss of *I*~MI~ voltage dependence in W7 is due to the loss of CaSR signaling due to receptor endocytosis ([@B38]), then the blockade of endocytosis is expected to prevent W7-induced reductions in *I*~MI~ voltage dependence. To test this, we constructed a 2 × 2 experimental design using CCAP to induce *I*~MI~. *I*~MI~ was measured in the presence of a 33 μ[m]{.smallcaps} concentration of the endocytosis inhibitor dynasore (cell-permeable dynamin inhibitor; IC~50~ for human Dyn1 and Dyn2, ∼15 µ[m]{.smallcaps}; [@B52]) and an effective concentration of W7 (i.e., 33 μ[m]{.smallcaps}; [Fig. 2](#F2){ref-type="fig"}). A two-way ANOVA for factors W7 and dynasore showed a significant increase in CCAP-induced *I*~MI~ slope with W7 (as also observed with proctolin-induced *I*~MI~; [Fig. 2*A*](#F2){ref-type="fig"}; W7: *F*~(1,32)~ = 14.934, *p* = 5.12 × 10^−4^; dynasore: *F*~(1,32)~ = 4.317, *p* = 0.046; interaction: *F*~(1,32)~ = 2.109, *p* = 0.156^ae^). The weak significance of the dynasore condition in this ANOVA originates entirely from the effect of dynasore in the presence of W7 ([Fig. 8*B*,*C*](#F8){ref-type="fig"}, green vs red: *post hoc* Tukey's test, *p* = 0.003; [Table 3](#T3){ref-type="table"}). CCAP-induced *I*~MI~ shows a markedly increased slope in the presence of 33 μ[m]{.smallcaps} W7 alone ([Fig. 8*A--C*](#F8){ref-type="fig"}, red) compared with control (black traces; *post hoc* Tukey's test, *p* \< 0.001; [Table 3](#T3){ref-type="table"}). However, in contrast to W7 alone, and consistent with our prediction, when cells were preincubated in 33 µ[m]{.smallcaps} dynasore, and then exposed to 33 µ[m]{.smallcaps} W7 in the presence of dynasore ([Fig. 8*B*,*C*](#F8){ref-type="fig"}, green), no significant difference was observed when compared with dynasore alone ([Fig. 8*B*,*C*](#F8){ref-type="fig"}, blue): *post hoc* Tukey's test, *p* = 0.129 ([Table 3](#T3){ref-type="table"}). Note that incubation in dynasore alone ([Fig 8*A--C*](#F8){ref-type="fig"}, blue) had no significant effect on *I*~MI~ slope compared with control (*p* = 0.624; [Table 3](#T3){ref-type="table"}). These results indicate that incubation in dynasore prevents W7-induced loss of voltage dependence of *I*~MI~. Although we did not expect a change in CCAP-induced amplitude at −15 mV, a two-way ANOVA for factors dynasore and W7 showed that W7, but not dynasore, produced significant changes in *I*~MI~ amplitude (W7: *F*~(1,32)~ = 8.738, *p* = 0.006; dynasore: *F*~(1,32)~ = 0.0001, *p* = 0.991; interaction: *F*~(1,32)~ = 1.472, *p* = 0.234^af^). However, a Tukey's test showed that this effect arose only from a significant difference between dynasore and W7 preincubated with dynasore (*p* = 0.011), while the other treatments did not significantly contribute to this trend.

![The endocytosis inhibitor dynasore prevents W7-induced increases in *I*~MI~ slope in LP neurons. CCAP-induced *I*~MI~ was measured before (black) and after exposure to the following: 33 µ[m]{.smallcaps} W7 for 45-65 min (red); dynasore for 45-80 min (blue); 20 min in 33 µ[m]{.smallcaps} dynasore, then 45-60 min in 33 µ[m]{.smallcaps} dynasore plus 33 µ[m]{.smallcaps} W7 (green). ***A***, Representative *I--V* curves of W7 effect (top) and dynasore effect (bottom). ***B***, Average *I--V* curves of all experiments. ***C***, Average slope of CCAP-induced *I*~MI~ from data in ***B*** and two-way ANOVA for the effects of factors dynasore and W7 on slope (W7: *F*~(1,32)~ = 14.934, *p* = 5.12 × 10^−4^; dynasore: *F*~(1,32)~ = 4.317, *p* = 0.046; Interaction: *F*~(1,32)~ = 2.109, *p* = 0.156^ae^). *Post hoc* Tukey's comparisons on slope: (1) W7 only vs control (*p* \< 0.001); (2) dynasore only vs control (*p* = 0.624); (3) dynasore only vs dynasore plus W7 (*p* = 0.129); and (4) W7 only vs W7 plus dynasore (*p* = 0.03). *Post hoc* Tukey's test: \**p* \< 0.05; \*\*\**p* \< 0.001.](enu0021620530008){#F8}

The specific CaSR agonist R568 reduces *I*~MI~ voltage dependence {#s4K}
-----------------------------------------------------------------

Because we observed an increase in the proctolin-induced *I*~MI~ slope in the presence of the CaSR antagonist NPS-2143, we predicted that incubation in the specific CaSR agonist R568 should decrease or leave the slope unaltered in normal calcium, but should make the slope more negative (restore voltage dependence) in low-calcium conditions. In contrast to our expectations, 10 µ[m]{.smallcaps} R568 increased both proctolin-induced *I*~MI~ slope and amplitude in both normal and low-calcium conditions ([Fig. 9*A*,*B*](#F9){ref-type="fig"}). A two-way ANOVA for factors R568 and calcium showed significant changes in proctolin-induced *I*~MI~ slope (calcium: *F*~(1,20)~ = 8.560, *p* = 0.008; R568: *F*~(1,20)~ = 9.295, *p* = 0.006; interaction: *F*~(1,20)~ = 0.0324, *p* = 0.859^ag^; [Fig. 9*C*](#F9){ref-type="fig"}). Instead of the slope decreasing as expected, a *post hoc* Tukey's test showed that in a normal calcium condition, the proctolin-induced *I*~MI~ slope increased upon exposure to R568 instead (*p* = 0.047). Likewise, in a low-calcium condition, R568 increased proctolin-induced *I*~MI~ slope (*p* = 0.041; [Fig. 9*C*](#F9){ref-type="fig"}, [Table 3](#T3){ref-type="table"}). These results are consistent with the hypothesis that CaSR modulates *I*~MI~ voltage dependence, but are inconsistent with the predicted direction of this modulation (see Discussion). In contrast with our expectation that *I*~MI~ amplitude should not be affected, a two-way ANOVA for factors R568 and calcium showed significant changes in proctolin-induced *I*~MI~ amplitude at −15 mV (calcium: *F*~(1,20)~ = 18.301, *p* = 3.67 × 10^−4^; R568: *F*~(1,20)~ = 23.447, *p* = 9.87 × 10^−5^; interaction: *F*~(1,20)~ = 5.962, *p* = 0.024^ah^). A *post hoc* Tukey test showed that the amplitude change was not significant in the normal calcium condition (*p* = 0.091) but was significant in the low-calcium condition (*p* \< 0.001; data not shown).

![The CaSR agonist R568 increases proctolin-induced *I*~MI~ slope in LP neurons. Proctolin-induced *I*~MI~ was measured in the presence (red) or absence (black) of 10 µ[m]{.smallcaps} CaSR agonist R568 in either 13 m[m]{.smallcaps} CaCl2 (solid) or 2 m[m]{.smallcaps} CaCl2 (striped). ***A***, Left, Representative *I--V* curves of proctolin-induced *I*~MI~ in 13 m[m]{.smallcaps} CaCl2 (black solid), 2 m[m]{.smallcaps} CaCl2 (black dotted), and 13 m[m]{.smallcaps} CaCl2 (green solid) after a 1 h wash. Right, Representative *I--V* curves of proctolin-induced *I*~MI~ in the presence of 10 µ[m]{.smallcaps} CaSR agonist R568 in normal (13 m[m]{.smallcaps}) calcium (red solid), low (2 m[m]{.smallcaps}) calcium (red dotted), and then in normal calcium after 1 h wash from R568 (green solid). ***B***, Left, Averaged *I--V* traces of all proctolin-induced *I*~MI~ experiments in normal calcium in the presence (red solid) or absence (black solid) of 10 µ[m]{.smallcaps} R568. Right, Averaged *I--V* traces of all proctolin-induced *I*~MI~ experiments in a low-calcium condition in the presence (red dotted) or absence (black dotted) of 10 µ[m]{.smallcaps} R568. ***C***, Quantification of *I*~MI~ slope. Two-way ANOVA for factors R568 and calcium showing significant changes in proctolin-induced *I*~MI~ slope (calcium: *F*~(1,20)~ = 8.560, *p* = 0.008; R568: *F*~(1,20)~ = 9.295, *p* = 0.006; interaction: *F*~(1,20)~ = 0.0324, *p* = 0.859^ag^). Error bars indicate the SEM. Tukey's test: \**p* \< 0.05; \*\*\**p* \< 0.001.](enu0021620530009){#F9}

Discussion {#s5}
==========

The voltage dependence of ion channels is most commonly due to the properties of a voltage sensor embedded in the structure of the ion channels themselves. Exceptions to this mechanism are the voltage-dependent block of NMDA channels by magnesium ([@B4]), a CaMKII-mediated phosphorylation of cGMP-activated channels in dogfish retinal bipolar cells ([@B79]), calcineurin-mediated voltage dependence in salamander bipolar cells ([@B80]), and activation of G-proteins in mammalian smooth muscle ([@B98]). Here we report evidence that a calmodulin-sensitive pathway activated by extracellular calcium-sensing receptors may constitute a novel mechanism of voltage dependence of the neuromodulator-activated *I*~MI~ in crab STG neurons.

Previous findings showed that extracellular calcium regulates the voltage dependence of *I*~MI~ in a manner analogous to the voltage-dependent magnesium block of NMDA channels ([@B29]). Subsequently, the calmodulin inhibitor W7 was found to affect *I*~MI~ amplitude and perhaps voltage dependence ([@B82]). Based on this, we predicted that activated calmodulin is directly or indirectly involved in the generation of *I*~MI~ voltage dependence ([Fig. 10](#F10){ref-type="fig"}, summary diagram). We hypothesized that the influx of calcium regulates calmodulin activity. This would explain the reduction of voltage dependence in low-extracellular calcium conditions. This was supported by our observations that calmodulin inhibitors reduced proctolin-induced *I*~MI~ voltage dependence ([Fig. 2](#F2){ref-type="fig"}). Also supporting this is the finding that the ryanodine receptor antagonist dantrolene similarly decreased *I*~MI~ voltage dependence ([Fig. 3](#F3){ref-type="fig"}), presumably by reducing intracellular calcium release. More indirect support was provided by inhibitors of calmodulin-activated proteins KN-93 and ML-7 ([Figs. 4](#F4){ref-type="fig"}, [7](#F7){ref-type="fig"}, [10](#F10){ref-type="fig"}), which are capable of reducing *I*~MI~ voltage dependence. Unexpectedly, we found that, although *I*~MI~ voltage dependence in the presence of normal calcium can be reduced by inhibitors of calmodulin, voltage dependence cannot be restored in low-calcium solutions by calmodulin activators (e.g., CALP1). These results led us to conclude that calmodulin is necessary but not sufficient to give rise to *I*~MI~ voltage dependence.

![A model for CaSR-mediated regulation of *I*~MI~ voltage dependence. According to this model, *I*~MI~ channels are activated by a neuropeptide receptor using a pathway (not shown here) independent from the depicted voltage dependence pathway. The voltage dependence of *I*~MI~ is regulated by G-protein-coupled CaSRs. Calmodulin (CaM) stabilizes the receptor on the membrane, and inhibitors of calmodulin lead to CaSR endocytosis. Green boxes and blunt-ended lines show agents that inhibit the indicated paths. Arrows indicate activating pathways. Intracellular calcium release via ryanodine receptors is part of the source for calmodulin activation, and both CaMKII and MLCK inhibit voltage dependence.](enu0021620530010){#F10}

A new hypothesis: the calcium-sensing receptor hypothesis {#s5A}
---------------------------------------------------------

We propose that calcium-sensing receptors actively monitor extracellular calcium activity and regulate *I*~MI~ voltage dependence via a separate pathway than its neuromodulator-dependent activation pathway ([Fig. 10](#F10){ref-type="fig"}). We are aware that this hypothesis does not represent a complete understanding of the mechanism of calcium-dependent voltage control of *I*~MI~, but identifies what we believe are major players in this system. We expect this hypothesis to constitute a framework for understanding our results and for a more detailed examination of these ideas and their implications in the future. A related mechanism has been proposed for the regulation of activation of leak currents in other systems ([@B51]). According to this hypothesis, when extracellular calcium is lowered, CaSR signaling to *I*~MI~ is reduced, and *I*~MI~ voltage dependence is consequently decreased. This is supported primarily by the finding that the CaSR antagonist NPS-2143 inhibits *I*~MI~ voltage dependence ([Fig. 6](#F6){ref-type="fig"}). Further, consistent with existing views of CaSR function ([@B38]), we claim that calmodulin antagonist-induced loss of voltage dependence is due to CaSR endocytosis, which is supported by our observation that endocytosis inhibitors prevent W7-induced reduction in voltage dependence ([Fig. 8](#F8){ref-type="fig"}). Although all our data were collected in LP cells, we predict that CaSR may play a similar role in modulating *I*~MI~ in all other neurons of the pyloric network since all display the peptide-induced current *I*~MI~ ([@B82]), at least one additional identified neuron (the PD neuron) has been shown to lose voltage dependence in low-calcium conditions ([@B96]), and Swensen and Marder (2000) showed that some additional unidentified neurons also show *I*~MI~ linearization in low-external calcium conditions.

Interestingly, the specific CaSR agonist R568 ([@B62]) did not restore *I*~MI~ voltage dependence in low-calcium conditions, as expected ([Fig. 9](#F9){ref-type="fig"}). In the absence of a positive control for R568 in crustaceans, one possible explanation consistent with a model of CaSR-mediating voltage dependence would be homologous desensitization of CaSR ([@B27]), with agonist-dependent phosphorylation and β-arrestin interactions as a possible mechanism ([@B71]; [@B59]; [@B6]; [@B51]; [@B91]; [@B89]), although CaSRs in other systems are noted for their resistance to desensitization ([@B31]; [@B12]; [@B17]). According to our model, the inability of R568 to restore voltage dependence in low-calcium conditions suggests that strong stimulation of CaSR by R568 could lead to endocytosis of the receptor and loss of voltage dependence. Future studies should test the effects of R568 in low-calcium conditions on CaSR after the inhibition of endocytosis or of G-protein receptor kinases with the expectation that this should lead to the restoration of *I*~MI~ voltage dependence.

Is CaSR signaling required for stable expression of neuromodulator-activated *I*~MI~? {#s5B}
-------------------------------------------------------------------------------------

We have observed that the desensitization of proctolin- and CCAP-induced *I*~MI~ is significantly faster in low-calcium compared with normal calcium conditions ([Table 2](#T2){ref-type="table"}). One possible explanation is that a minimum amount of CaSR signaling may be required to stabilize *I*~MI~ channels and their activation by neuromodulators. It is unclear, however, whether this would occur at the level of neuromodulator receptors, second messenger pathways, or the *I*~MI~ channels. In agreement with *I*~MI~ requiring activated CaSR signaling is the finding that the inhibition of MLCK, a suspected CaSR second messenger ([@B18]), reduced *I*~MI~ amplitude. However, NPS-2143, a CaSR antagonist, would then be expected to reduce *I*~MI~ activation, something we did not observe. Further, gallein, which is known to reduce plasma membrane expression of CaSR and phosphoinositide hydrolysis in response to CaSR agonists in other systems ([@B31]), should, in this case, reduce *I*~MI~ amplitude. We have in fact observed an inhibiting effect of gallein on *I*~MI~, but this was not statistically significant. Unfortunately, without a direct assay for CaSR, we cannot determine directly whether gallein is affecting CaSR receptor expression. An indirect means for assaying this in future studies would be to survey the ability of NPS-2143 to alter *I*~MI~ voltage dependence at different gallein concentrations.

Is voltage dependence a target for meta-modulation? {#s5C}
---------------------------------------------------

The findings that voltage dependence may be modulated by a G-protein-coupled CaSR, together with the finding that the Gβγ inhibitor gallein reduced *I*~MI~ voltage dependence, implicating the G-protein βγ-subunit in the regulation of *I*~MI~ voltage dependence, suggests that voltage dependence itself could be a target of neuromodulation. Consistent with this is the observation of [@B96] that the negative linear slope region of the *I--V* curve of *I*~MI~ is all that is required to induce oscillatory activity in this system. This observation was used to claim that *I*~MI~ in these cells is a pacemaker current ([@B96]). This indicates that oscillatory activity could be regulated by modulation of the voltage dependence, in addition to the activation levels, of a current. Voltage dependence has been shown to be a target of second messenger pathways before, albeit in a nonoscillatory system ([@B98]; [@B61]; [@B79]; [@B80]). Therefore, it would be interesting to examine the comodulation in this system in further detail to see whether voltage dependence itself could be the direct target of neuromodulation.

To conclude, the novel role for extracellular calcium reported here adds another layer of complexity to the role of calcium in the regulation of neuronal activity. Besides its ubiquitous role as intracellular second messenger of calcium, there is mounting evidence that calcium plays an increasingly important role as an extracellular ligand. Not only does calcium regulation play a vital role in parathyroid ([@B36]; [@B55]; [@B71]), bone ([@B44]), intestine ([@B14]; [@B18]; [@B31]), and kidney function ([@B2]), but increasingly also in the modulation of neuronal activity ([@B59]; [@B6]; [@B51]; [@B91]; [@B89]).

What is the physiological role of CaSR in the stomatogastric ganglion? {#s5D}
----------------------------------------------------------------------

A[@B96] have suggested, the negative slope conductance region of *I*~MI~ controls the oscillatory character of these neurons. Thus, local extracellular calcium concentration changes could create a gradient of activity from tonic spiking at low concentrations, where *I*~MI~ is less voltage dependent, to the classic triphasic pyloric slow rhythm at normal calcium concentrations, in which negative slope conductance is present. Thus, the crucial question is: do extracellular calcium levels change significantly for CaSR activity to be affected? In contrast to vertebrates, in invertebrates extracellular calcium can vary dramatically during molting ([@B100]; [@B1]). On the other hand, in other systems, CaSR has been proposed to inhibit synaptic release when extracellular calcium levels are high through a presynaptic mechanism. In this mechanism, CaSR inhibits a nonselective cation current in normal calcium conditions, but when local extracellular calcium drops, disinhibition of this current compensates for the expected drop in synaptic release probability ([@B70]; [@B43]). In mammals, local external calcium is known to vary significantly under different conditions, both normal and pathological, as follows: reductions of up to ∼30% are observed after 30 s of stimulation in cerebellum ([@B64]; [@B63]); reductions of \>50% are observed during seizure activity in cerebral cortex ([@B35]); overall depletion occurs in hippocampus ([@B74]); and significant decreases occur in dorsal root ganglion ([@B26]). Furthermore, in agreement with the activity of neurons being controlled by external calcium concentration, is the finding that CaSR is expressed in neurons in hippocampus ([@B59]; [@B48]; [@B5]; [@B21]), cerebellum ([@B45]), cortex ([@B45]; [@B70]; [@B90]), striatum after experimentally induced stroke ([@B65]), and sensory neurons ([@B91]). If similar changes in external calcium levels were demonstrated in the STG, then CaSRs could indeed regulate pyloric activity by modifying the level of *I*~MI~ voltage dependence.

Finally, it is possible that CaSR functions as a sensor of amino acid level fluctuations, as it is known to do in the mammalian intestine ([@B17]). This would add another level of modulation of the pyloric network that has not yet been explored.
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Synthesis {#s6}
=========

The decision was a result of the Reviewing Editor Alfonso Araque and the peer reviewers coming together and discussing their recommendations until a consensus was reached. A fact-based synthesis statement explaining their decision and outlining what is needed to prepare a revision is listed below. The following reviewers agreed to reveal their identity: Abdel EI Manira, Ronald Calabrese

Synthesis of the reviews

I concur with the reviewers\' comments expressing the interest and quality of the study. And I also consider pertinent the concerns expressed. I believe that addressing those concerns, which is probably relatively easy, will definitely improve the manuscript.

Specific comments of the reviewers:

Reviewer 1.

This study describes a novel mechanism of voltage-dependent neuromodulation in stomatogastric ganglion neurons. This manuscript extends on previous studies related to voltage-dependent modulation of an inward current and provides convincing evidence that, unlike what was previously thought, the voltage-dependence involves activation of a calcium sensing receptor. The figures are clear and easy to follow and the manuscript is well written.

I have only a few minor comments/suggestions to be considered by the authors when revising this manuscript.

1\) It is not clear which neurons were record in this study. Do all neurons in the STG exhibit this voltage-dependent neuromodulation? It would be helpful to clarify which neurons were recorded and if the effect studied is ubiquitous to all neurons.

2\) I am curious to see what effect does the antagonist of the CaSR has on the rhythmic motor pattern of the stomatogastric ganglion. i) does it affect the pyloric rhythm? ii) Does it alter the magnitude of the effects of proctolin or CCAP? This information, if available, would be valuable to link this novel neuromodulatory mechanisms to network function.

Reviewer 2.

The authors present pharmacological analysis of an important current that is modulator activated. This current activated by a plethora of peptides is called IMI and is found in many neurons of the important model system, the crustacean stomatogastric nervous system (STN). It is a voltage dependent slow inward current mainly carried by Na+ and is characterized by a negative slope resistance in it IV plot. It is a relatively small current, derived as a difference current in voltage-clamp ramp protocols, but it is an important determinant of rhythmicity in the STN. From it first discovery by Freschi (1989), it has been enigmatic because its IV plot loses in negative slope resistance in low calcium saline and becomes a linear leak-like current. Until this study the current hypothesis concerning this linearization was that there was a voltage dependent Ca2+ block analogous to the Mg2+ block of NMDA channels. This view was complicated by the observation of Swensen and Marder (2000) that the calmodulin blocker W7 enhanced IMI in a voltage-dependent manner and concluded that a calmodulin-dependent pathway was likely involved in IMI activation. This study aims to show that the situation is much more complex; it purports to show that the Ca sensitivity of voltage dependence is mediated by CaSRs and involves calmodulin, MLCK, and CamKII.

This reviewer cannot critically evaluate the subtleties of the pharmacological characterization; I have little experience with the drugs used and cannot comment on their appropriateness or specificity. I therefore give the benefit of the doubt that the drugs work as advertised. Nevertheless the results are sufficiently complex and not without surprises/conflicts so that the whole story in not totally clear and certainly not definitive. On the other hand, there is a truly tremendous amount of experimental work here and the data is carefully analyzed and statistically tested. One also wishes that the difference currents were not so heterogeneous and squiggly looking but the current is a small one on a large leak background; I tend to trust that the experimenters know what they are measuring.

Two concerns reduce my enthusiasm for this work.

1\. The results do not give a complete or definitive picture but seem rather to identify players and to require some hand-waving (CaSR agonist effects) to result in a model that is more a framework than a mechanistic understanding (Fig. 10).

2\. Try as they might in Discussion the authors fail to convince me that the elaborate mechanism they suggest has physiological meaning: what are physiological conditions under which voltage sensitivity would be modulated by this mechanism and to what function?

Minor Concerns:

1\. Line 21: \"\...and CaSR agonists and antagonists affected IMI voltage-dependence.\" seems to hide a lot of complexity especially in Abstract. Agonists have effects opposite prediction.

2\. Line 325 and subsequent section; in the absence of a positive control for efficacy in this system the CALP1 results are not definitive.

3\. Line 339 and subsequent section: Experiments that increase intracellular Ca2+ from stores in low external Ca2+ seems important here. Thapsigargin????

4\. Lines 375-77: \"These results (for dantrolene) are consistent with previous calmodulin inhibitor results, which suggest a role for intracellular calcium and calmodulin in the regulation of IMI voltage-dependence.\" Why is there no conclusion about activation when similar data for KN-93 mentions effects on both voltage dependence and activation.

5\. Fig. 4A: There is no mention in the text of the green dashed line or is there reference to prolonged applications of KN-93.

6\. Line 428-31: These two sentences are confusingly redundant.

7\. Fig 9C: Displaced Y-axis labels.

8\. Lines 565-72: This is an inappropriate personal communication. We cannot judge the likelihood of a CaSR critically based on such evidence.

7\. Lines 583-86: There appear to be missing words.

8\. Lines 627-29: Besides the ubiquitous role of calcium as an intracellular second messenger, there is mounting evidence that calcium plays an increasingly important role as an extracellular ligand
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